<li>budesonide<p>famotidine decreases effects of budesonide by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Enteric-coated budesonide dissolves at pH &gt;5.5. Also, dissolution of extended-release budesonide tablets is pH dependent. Coadministration with drugs that increase gastric pH may cause these budesonide products to prematurely dissolve, and possibly affect release properties and absorption of the drug in the duodenum.</p></li><li>carbonyl iron<p>famotidine will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cefdinir<p>famotidine will decrease the level or effect of cefdinir by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cefditoren<p>famotidine will decrease the level or effect of cefditoren by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cefpodoxime<p>famotidine will decrease the level or effect of cefpodoxime by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cefuroxime<p>famotidine will decrease the level or effect of cefuroxime by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>crizotinib<p>famotidine decreases levels of crizotinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that elevate the gastric pH may decrease the solubility of crizotinib and subsequently reduce its bioavailability. However, no formal studies have been conducted. .</p></li><li>cyclosporine<p>famotidine will increase the level or effect of cyclosporine by  unknown mechanism. Modify Therapy/Monitor Closely.</p></li><li>dabrafenib<p>famotidine will decrease the level or effect of dabrafenib by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that alter upper GI tract pH (eg, PPIs, H2-blockers, antacids) may decrease dabrafenib solubility and reduce its bioavailability</p></li><li>dexmethylphenidate<p>famotidine will increase the level or effect of dexmethylphenidate by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Applies only to extended release formulation</p></li><li>erlotinib<p>famotidine decreases levels of erlotinib by Other (see comment). Use Caution/Monitor. 
Comment: Avoid combination when possible. If  concurrent use is required erlotinib should be taken 10 hours after a H2-antagonist and at least 2 hours before the next dose of H2-antagonist.</p></li><li>ferrous fumarate<p>famotidine will decrease the level or effect of ferrous fumarate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous gluconate<p>famotidine will decrease the level or effect of ferrous gluconate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous sulfate<p>famotidine will decrease the level or effect of ferrous sulfate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>fosamprenavir<p>famotidine will decrease the level or effect of fosamprenavir by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>gefitinib<p>famotidine decreases levels of gefitinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Separate gefitinib and H2-antagonist doses by at least 6 hr.</p></li><li>glipizide<p>famotidine will increase the level or effect of glipizide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>glyburide<p>famotidine will increase the level or effect of glyburide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>iron dextran complex<p>famotidine will decrease the level or effect of iron dextran complex by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>iron sucrose<p>famotidine will decrease the level or effect of iron sucrose by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ledipasvir/sofosbuvir<p>famotidine decreases levels of ledipasvir/sofosbuvir by Other (see comment). Use Caution/Monitor. 
Comment: Ledipasvir solubility decreases as pH increases; drugs that increase gastric pH are expected to decrease levels of ledipasvir; H2-receptor antagonists may be administered simultaneously with or 12 hr apart from ledipasvir/sofosbuvir at a dose that does not exceed doses comparable to famotidine 40 mg BID.</p></li><li>mesalamine<p>famotidine will decrease the level or effect of mesalamine by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely.</p></li><li>methylphenidate<p>famotidine will increase the level or effect of methylphenidate by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Applies only to extended release formulation</p></li><li>mifepristone<p>famotidine, mifepristone.
Either increases toxicity of the other by QTc interval. Use Caution/Monitor.<span><br><br></span>mifepristone, famotidine.
Either increases toxicity of the other by QTc interval. Use Caution/Monitor.</p></li><li>mycophenolate<p>famotidine will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>nelfinavir<p>famotidine will decrease the level or effect of nelfinavir by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>nilotinib<p>famotidine decreases levels of nilotinib by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Avoid this interaction by administering H2 antagonists 10 hr after or 2 hr before nilotinib.</p></li><li>polysaccharide iron<p>famotidine will decrease the level or effect of polysaccharide iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>posaconazole<p>famotidine will decrease the level or effect of posaconazole by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>rilpivirine<p>famotidine, rilpivirine. increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Combination of rilpivirine and H2-receptor antagonists should be used with caution as coadministration may cause significant decreases in rilpivirine plasma concentrations (increase in gastric pH). Administer famotidine at least 12 hours before or at least 4 hours after rilpivirine.</p></li><li>rose hips<p>famotidine will decrease the level or effect of rose hips by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>saquinavir<p>famotidine will increase the level or effect of saquinavir by  unspecified interaction mechanism. Use Caution/Monitor.</p></li><li>sofosbuvir/velpatasvir<p>famotidine will decrease the level or effect of sofosbuvir/velpatasvir by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Velpatasvir solubility decreases as gastric pH increases (practically insoluble at pH &gt;5). H2 receptor antagonists may be administered simultaneously with or 12 hr apart from sofosbuvir/velpatasvir at a dose that does not exceed doses comparable to famotidine 40 mg BID.</p></li><li>sulpiride<p>famotidine will decrease the level or effect of sulpiride by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>tolbutamide<p>famotidine will increase the level or effect of tolbutamide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>varenicline<p>famotidine will increase the level or effect of varenicline by  decreasing renal clearance. Use Caution/Monitor.</p></li><li>vismodegib<p>famotidine will decrease the level or effect of vismodegib by  Other (see comment). Use Caution/Monitor. Drugs that increase gastric pH alter vismodegib solubility and therefore reduce bioavailability; effect on efficacy unknown</p></li>